OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Rheumatology is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	870
Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease	842
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	304
Thrombotic microangiopathy as a presentation of anti-synthetase syndrome	189
A disseminated gonococcal infection with spinal locations	188
Biological disease-modification in axial spondyloarthritis: insights from MRI	133
Research in Brief	133
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?	131
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases	115
Can contextual factors improve clarity of the results from clinical trials of low back pain?	114
COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1	112
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	111
Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial	100
Reigniting the burnt-out health-care workforce	96
From phenotype to pathophysiology—placing rheumatic diseases in an immunological perspective	90
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study	86
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries	82
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	76
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial	74
Women in rheumatology in Africa	70
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica due to lumbar disc herniation	66
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?	66
Early-stage Dupuytren's disease treatment; a promising next step?	58
Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?	58
Juvenile systemic lupus erythematosus presenting as retinal vasculitis	56

Pausing drugs and spacing vaccines: an open question – Authors' reply	56
Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus	55
The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study	54
Reclassifying ANCA-associated vasculitis: a focus on kidney disease	46
Research in Brief	46
Outdoor temperatures and Raynaud's phenomenon in patients with systemic sclerosis	45
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study	45
Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis	44
Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE	44
Composite endpoints for Sjögren's Syndrome	44
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study	43
Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus	43
Biosimilars and the era of interchangeability	42
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial	42
Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts	42
Assessing glucocorticoid toxicity: are the measures sensitive enough?	42
Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial	42